ArticleChemical biology & drug design2026
An Anoikis-Related Gene Signature Associated With Stromal Remodeling and Clinical Outcome in Gastric Cancer.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a highly aggressive malignancy with poor prognosis. Anoikis resistance is closely associated with tumor progression and metastasis, but the prognostic and functional relevance of anoikis-related genes (ARGs) in GC remains incompletely understood. Public transcriptomic, clinical, somatic mutation, and single-cell RNA sequencing (scRNA-seq) datasets were integrated to identify differentially expressed ARGs, develop an ARG-based risk model, and investigate its associations with tumor microenvironment (TME) features. In vitro experiments were performed to assess the effects of selected candidate genes on GC cell migration and invasion. Forty-five differentially expressed ARGs were identified in The Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) cohort. An ARG-based risk model was developed using the TCGA-STAD cohort and evaluated in the GSE84437 cohort. The model was associated with overall survival and provided potential value for risk stratification, although its discriminative performance was modest. High-risk patients showed distinct immune, stromal, and somatic mutational features. Single-cell analysis suggested that ARG-related transcriptional programs were associated with stromal remodeling and endothelial-to-mesenchymal transition (EndMT)-associated features in the GC microenvironment. Among the core ARGs, EEF1A2 and TAGLN showed prognostic relevance and higher protein expression in GC tissues. Small interfering RNA (siRNA)-mediated knockdown of either gene reduced the migration and invasion of HGC-27 cells. These findings indicate that ARG-related molecular features are associated with GC prognosis and immune-stromal characteristics, while EEF1A2 and TAGLN may represent candidate genes related to GC cell migration and invasion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.